Therapeutic Antibodies to Ganglioside GD2 Evolved from Highly Selective Germline Antibodies

Antibodies against GD2 ganglioside can eradicate syngeneic cancer micrometastases.

After 10 years of clinical trials in patients with advanced cancer, monoclonal antibodies (mAbs) against cell surface antigens have not lived up to their initial promise. One such cell surface antigen is the ganglioside GD2. GD2 is richly expressed at the cell surfaces of human neuroblastomas, sarcomas, and melanomas. We have described a murine lymphoma (EL4) that is syngeneic in C57BL/6 mice a...

Antibodies against GD2 Ganglioside Can Eradicate Syngeneic Cancer Micrometastases1

After 10 years of clinical trials in patients with advanced cancer, monoclonal antibodies iniAhsi against cell surface antigens have not lived up to their initial promise. One such cell surface antigen is the ganglioside GD2. GD2 is richly expressed at the cell surfaces of human neuroblastomas, sarcomas, and melanomas. We have described a murine lymphoma (EL4) that is syngeneic in C57BL/6 mice ...

Detection of Anti-Ganglioside Antibodies in Guillain-Barre Syndrome

“Therapeutic Antibodies”

This book attempts and to a great extent achieves, its apparent object to review brain tumours in a comprehensive manner. It is a series of chapters by appropriate experts ranging in subject from molecular genetics, through clinical presentation, investigations to the various forms of management. It is up-to-date. The book's editors are well known and credible-a neurosurgeon and a neuropatholog...

Monoclonal Antibodies as Therapeutic Agents: Advances and Challenges

Despite the major advances in conventional forms of treatment (i.e. surgical techniques, radiotherapy and chemotherapy) and improved survival rates, cancer is still the second leading cause of death in developing countries. One major limitation of cytotoxic drugs and radiation in the treatment of cancer patients is their inability to discriminate between malignant and normal tissues. This in tu...